NOVALEX THERAPEUTICS, INC.

Biotech · Private

Small-molecule NS3/4A protease inhibitors for hepatitis C virus with broad genotype coverage and reduced resistance

Grants
$599K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors$300,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility$298,502
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1620DASFANH BIOSCIENCES, LLC——
1621Verdiva Bio——
1622Furtim Therapeutics LLC——
1623NOVALEX THERAPEUTICS, INC.——
1624RADIKAL THERAPEUTICS, INC.——
1625Chan Zuckerberg Biohub——
1626ERADIVIR, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Enoyl Reductase Inhibitors With Antibacterial Activityapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.